Holen Sie sich die Stockscreener-App
3.07
3.15%
-0.10
Schlusskurs vom Vortag:
$3.17
Offen:
$3.06
24-Stunden-Volumen:
9,704
Relative Volume:
0.55
Marktkapitalisierung:
$5.82M
Einnahmen:
Nettoeinkommen (Verlust:
$-10.21M
KGV:
-5.255
EPS:
-0.5842
Netto-Cashflow:
$-4.10M
1W Leistung:
-16.12%
1M Leistung:
-52.70%
6M Leistung:
-78.32%
1J Leistung:
-87.42%
1-Tages-Spanne:
$3.06
$3.24
1-Wochen-Bereich:
$2.87
$3.784
52-Wochen-Spanne:
$2.87
$26.64
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Firmenname
Neurosense Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare NRSN vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
3.07 | 5.82M | 0 | -10.21M | -4.10M | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
$1 bid-price compliance regained, but NeuroSense (Nasdaq: NRSN) still faces a listing deficiency. - Stock Titan
The $1 share-price rule is met, but NeuroSense still faces another Nasdaq listing test. - Stock Titan
NRSN Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 7.14%Earnings Forecast Report - https://www.dars.gov.et/
NeuroSense Regains Nasdaq Bid Price Compliance, Appeals Market Value Delisting Notice - The Globe and Mail
The $1 bid-price hurdle is cleared, but NeuroSense (Nasdaq: NRSN) still faces delisting. - Stock Titan
NeuroSense Provides Update on Nasdaq Listing Compliance - Moomoo
A $35 million Nasdaq market-value rule remains unmet; NeuroSense plans to seek more time. - Stock Titan
NeuroSense Provides Update on Nasdaq Listing Compliance - TradingView
Without delays, cash won't fund 12 months under NeuroSense's (NASDAQ: NRSN) original development plan. - Stock Titan
NeuroSense Provides Business Update and Progress for the First Half of 2026 - Morningstar
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq - The Globe and Mail
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq - The Globe and Mail
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq - TipRanks
12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com
NeuroSense (NASDAQ: NRSN) cuts share count to 1.9M in 1-for-20 split - Stock Titan
NRSN 6-K & SEC Filings - Yahoo! Finance Canada
Why Is NeuroSense (NASDAQ:NRSN) in Focus Before Tuesday’s Open? - kalkinemedia.com
Amyotrophic Lateral Sclerosis Pipeline 2026: FDA Approvals, - openPR.com
NeuroSense Therapeutics (NRSN) Slips 1.24% to $0.41, Hovering Near Key Support at $0.39Parabolic SAR - dars.gov.et
NeuroSense Therapeutics (NRSN) Slips 1.24% to $0.41, Hovering Near Key Support at $0.39Trade Entry Signals - dars.gov.et
NeuroSense Therapeutics (NRSN) Slips 1.24% to $0.41, Hovering Near Key Support at $0.39Ascending Triangle - dars.gov.et
NRSN Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS - Morningstar
NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval - TipRanks
NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval - Benzinga
NeuroSense (NRSN) gains 12‑month mandate for reverse share split - Stock Titan
NeuroSense Therapeutics Ltd. Warrant (NRSNW) Peer Comparison – Compare with Others - Value Research
NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSN - TradingView
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - vinanet.vn
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session: Support at $0.36 and Resistance at $0.40 Frame the Range for the Current SessionValue Area High - careplusvn.com
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session: Support at $0.36 and Resistance at $0.40 Frame the Range for the Current SessionThrowback Trade - siam.in
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - dars.gov.et
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - dars.gov.et
Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - The Globe and Mail
Amyotrophic Lateral Sclerosis Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - openPR.com
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - TipRanks
NeuroSense Issues CEO Letter to Shareholders - Nasdaq
NeuroSense Issues CEO Letter to Shareholders - webull.com
NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorNHNL Ratio - dars.gov.et
NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorAnchored VWAP - dars.gov.et
Global Neurodegenerative Disease Market is Expected to - GlobeNewswire
NeuroSense Therapeutics (NRSN) Dips 1.6% to $0.49, Testing Key Support at $0.47PCR Moving Average - dars.gov.et
NeuroSense Therapeutics (NRSN) Dips 1.6% to $0.49, Testing Key Support at $0.47Price Surge Stocks - dars.gov.et
NRSN Q2 2025 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Pipeline AdvancesMid-Term Outlook - dars.gov.et
NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process - TipRanks
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - GuruFocus
Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan
Finanzdaten der Neurosense Therapeutics Ltd-Aktie (NRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neurosense Therapeutics Ltd-Aktie (NRSN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ben-Noon Alon | Chief Executive Officer |
Jun 16 '26 |
Buy |
0.80 |
250,000 |
200,000 |
4,534,233 |
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):